Overview

Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To provide early access and to evaluate the safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF)
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Nintedanib